Doctorante du Laboratoire Parcours de Santé Systémique UR 4129
Université Claude Bernard Lyon 1

Ecole Doctorale EDISS

Activité professionnelle actuelle : Employée de Takeda.

Thèse en cours : Identification et évaluation des facteurs implicites influant dans les décisions finales de remboursement des médicaments en Europe et Canada.

Global healthcare expenditures have been rising sharply and drug costs are a major factor. High prices of innovative medicines entering into the market are challenging increasingly the public health care systems, its sustainability and patients´ affordability. To ensure that the access of innovative health technologies and medicines to the healthcare system is made without endangering the system sustainability, a multidisciplinary and standardized process is set to do recommendations in an objective and transparent way. Here is where the Health Technologies Assessment (HTA) comes into action, informing policy and clinical decision making around the introduction of health technologies. The HTA process plays an important role as its recommendations can lead to the acceptance or rejection of medicines by the governmental bodies. However, this deliberative process may differ from one country to another and it is not always standardized and harmonized. There are intrinsic qualitative elements influencing the final decision and these are not clear and explicit.